Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Single-Cell Analysis | 10 | 2024 | 23 | 3.050 |
Why?
|
| Administration, Intranasal | 3 | 2024 | 11 | 2.540 |
Why?
|
| T-Lymphocytes | 9 | 2025 | 46 | 2.500 |
Why?
|
| Immunotherapy, Adoptive | 10 | 2025 | 21 | 2.430 |
Why?
|
| Neoplasms | 7 | 2024 | 90 | 1.920 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 3 | 1.640 |
Why?
|
| Nanoparticles | 2 | 2024 | 69 | 1.570 |
Why?
|
| Humans | 36 | 2025 | 4936 | 1.560 |
Why?
|
| Killer Cells, Natural | 6 | 2024 | 32 | 1.480 |
Why?
|
| Time-Lapse Imaging | 6 | 2024 | 9 | 1.470 |
Why?
|
| Transcriptome | 4 | 2021 | 43 | 1.440 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2024 | 37 | 1.410 |
Why?
|
| B-Lymphocytes | 3 | 2019 | 7 | 1.100 |
Why?
|
| Animals | 20 | 2024 | 1711 | 1.070 |
Why?
|
| Autoantibodies | 3 | 2019 | 5 | 1.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 184 | 1.030 |
Why?
|
| Mice | 14 | 2024 | 685 | 1.020 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 48 | 0.950 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2024 | 9 | 0.930 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 13 | 0.910 |
Why?
|
| Immunoglobulin G | 4 | 2024 | 25 | 0.890 |
Why?
|
| Tuberculosis Vaccines | 1 | 2024 | 2 | 0.850 |
Why?
|
| Antigens, Bacterial | 1 | 2024 | 3 | 0.850 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2024 | 10 | 0.850 |
Why?
|
| Algorithms | 2 | 2024 | 241 | 0.840 |
Why?
|
| Chymotrypsin | 3 | 2019 | 5 | 0.840 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2024 | 97 | 0.830 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 8 | 0.810 |
Why?
|
| Immunophenotyping | 3 | 2021 | 8 | 0.810 |
Why?
|
| Cytokines | 5 | 2024 | 37 | 0.800 |
Why?
|
| Salicylic Acid | 2 | 2022 | 3 | 0.760 |
Why?
|
| CD2 Antigens | 1 | 2022 | 1 | 0.760 |
Why?
|
| CD58 Antigens | 1 | 2022 | 1 | 0.760 |
Why?
|
| Arabidopsis Proteins | 1 | 2021 | 1 | 0.720 |
Why?
|
| Synthetic Biology | 1 | 2021 | 8 | 0.720 |
Why?
|
| Cell Nucleus | 1 | 2021 | 16 | 0.710 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2024 | 13 | 0.700 |
Why?
|
| High-Throughput Screening Assays | 4 | 2019 | 12 | 0.690 |
Why?
|
| 4-1BB Ligand | 1 | 2021 | 1 | 0.690 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2019 | 12 | 0.680 |
Why?
|
| Leukemia | 1 | 2021 | 6 | 0.680 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 13 | 0.670 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 20 | 0.650 |
Why?
|
| Flow Cytometry | 4 | 2016 | 39 | 0.610 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 6 | 0.610 |
Why?
|
| Autoimmunity | 1 | 2019 | 5 | 0.610 |
Why?
|
| Cytotoxicity, Immunologic | 8 | 2025 | 19 | 0.600 |
Why?
|
| Escherichia coli | 3 | 2019 | 111 | 0.580 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2017 | 4 | 0.570 |
Why?
|
| Plasmids | 2 | 2015 | 19 | 0.560 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 12 | 0.550 |
Why?
|
| Female | 8 | 2024 | 2523 | 0.540 |
Why?
|
| Cell Line, Tumor | 11 | 2025 | 160 | 0.510 |
Why?
|
| Signal Transduction | 6 | 2025 | 216 | 0.470 |
Why?
|
| Receptors, Antigen | 1 | 2015 | 1 | 0.450 |
Why?
|
| DNA | 1 | 2015 | 58 | 0.440 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 1 | 0.440 |
Why?
|
| Cricetinae | 2 | 2024 | 21 | 0.430 |
Why?
|
| Microscopy, Video | 2 | 2024 | 3 | 0.420 |
Why?
|
| Antigens, CD19 | 3 | 2022 | 4 | 0.390 |
Why?
|
| Interleukin-15 | 2 | 2024 | 2 | 0.390 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2013 | 1 | 0.390 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 8 | 0.390 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2024 | 29 | 0.390 |
Why?
|
| Cell Membrane | 1 | 2012 | 48 | 0.370 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2024 | 17 | 0.330 |
Why?
|
| Gene Expression | 5 | 2022 | 49 | 0.330 |
Why?
|
| Granzymes | 2 | 2024 | 2 | 0.320 |
Why?
|
| HEK293 Cells | 3 | 2021 | 30 | 0.310 |
Why?
|
| Biomarkers | 3 | 2020 | 81 | 0.300 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 96 | 0.280 |
Why?
|
| Rats | 2 | 2024 | 241 | 0.280 |
Why?
|
| CD28 Antigens | 2 | 2025 | 5 | 0.280 |
Why?
|
| Protein Transport | 2 | 2021 | 30 | 0.270 |
Why?
|
| Receptors, IgG | 2 | 2017 | 4 | 0.270 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2024 | 10 | 0.260 |
Why?
|
| Cell Communication | 2 | 2019 | 14 | 0.260 |
Why?
|
| Cells, Cultured | 3 | 2015 | 127 | 0.240 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 7 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 18 | 0.240 |
Why?
|
| Immunological Synapses | 1 | 2025 | 1 | 0.220 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 2 | 0.220 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 225 | 0.220 |
Why?
|
| Glypicans | 1 | 2024 | 1 | 0.220 |
Why?
|
| Antigens, Neoplasm | 3 | 2022 | 8 | 0.220 |
Why?
|
| Tumor Escape | 2 | 2022 | 4 | 0.220 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 32 | 0.220 |
Why?
|
| Antigens, Viral | 1 | 2024 | 4 | 0.220 |
Why?
|
| Mesocricetus | 1 | 2024 | 4 | 0.220 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2024 | 4 | 0.220 |
Why?
|
| Nucleotides, Cyclic | 1 | 2024 | 4 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 1 | 2024 | 21 | 0.220 |
Why?
|
| Antiviral Agents | 1 | 2024 | 16 | 0.210 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 5 | 0.210 |
Why?
|
| Immunity, Mucosal | 1 | 2024 | 1 | 0.210 |
Why?
|
| Acyltransferases | 1 | 2024 | 2 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 1 | 2024 | 5 | 0.210 |
Why?
|
| CD8 Antigens | 2 | 2021 | 2 | 0.210 |
Why?
|
| Tuberculosis | 1 | 2024 | 4 | 0.210 |
Why?
|
| CRISPR-Cas Systems | 2 | 2021 | 9 | 0.210 |
Why?
|
| Biological Products | 1 | 2024 | 9 | 0.210 |
Why?
|
| Lung | 1 | 2024 | 35 | 0.210 |
Why?
|
| Annexins | 1 | 2023 | 1 | 0.210 |
Why?
|
| Membrane Proteins | 1 | 2024 | 47 | 0.200 |
Why?
|
| Peptides | 2 | 2015 | 49 | 0.200 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 56 | 0.200 |
Why?
|
| Phenotype | 2 | 2021 | 67 | 0.200 |
Why?
|
| K562 Cells | 2 | 2021 | 10 | 0.200 |
Why?
|
| Immunologic Memory | 3 | 2017 | 4 | 0.180 |
Why?
|
| Lentivirus | 1 | 2022 | 3 | 0.180 |
Why?
|
| Genetic Vectors | 1 | 2022 | 7 | 0.180 |
Why?
|
| Cytoplasm | 1 | 2021 | 4 | 0.180 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 2024 | 2 | 0.180 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 1 | 0.170 |
Why?
|
| CD4 Antigens | 1 | 2021 | 1 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2021 | 20 | 0.170 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2021 | 1 | 0.170 |
Why?
|
| Mice, SCID | 1 | 2021 | 9 | 0.170 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 1 | 0.170 |
Why?
|
| Fetal Blood | 1 | 2021 | 3 | 0.170 |
Why?
|
| Mutation, Missense | 1 | 2021 | 7 | 0.170 |
Why?
|
| Amyloid | 1 | 2021 | 9 | 0.170 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 27 | 0.170 |
Why?
|
| Male | 3 | 2024 | 2491 | 0.170 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 25 | 0.170 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 17 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 29 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 21 | 0.170 |
Why?
|
| Genomics | 1 | 2021 | 38 | 0.170 |
Why?
|
| Green Fluorescent Proteins | 2 | 2022 | 22 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 1 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2022 | 8 | 0.160 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 73 | 0.160 |
Why?
|
| Glycosylation | 1 | 2019 | 10 | 0.160 |
Why?
|
| Substrate Specificity | 1 | 2019 | 16 | 0.160 |
Why?
|
| Microfluidics | 1 | 2019 | 8 | 0.150 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 1 | 0.150 |
Why?
|
| ErbB Receptors | 1 | 2019 | 4 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 14 | 0.150 |
Why?
|
| Software | 1 | 2019 | 57 | 0.140 |
Why?
|
| Microscopy | 1 | 2019 | 35 | 0.140 |
Why?
|
| GPI-Linked Proteins | 1 | 2017 | 1 | 0.130 |
Why?
|
| CD56 Antigen | 1 | 2017 | 2 | 0.130 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2017 | 2 | 0.130 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2017 | 5 | 0.130 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 9 | 0.130 |
Why?
|
| Complement C1q | 1 | 2017 | 1 | 0.130 |
Why?
|
| Phagocytosis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 3 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2016 | 4 | 0.120 |
Why?
|
| Immune System | 1 | 2016 | 11 | 0.120 |
Why?
|
| Peptide Library | 1 | 2015 | 4 | 0.120 |
Why?
|
| Pyrones | 1 | 2015 | 5 | 0.120 |
Why?
|
| Cell Tracking | 1 | 2015 | 5 | 0.120 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 42 | 0.110 |
Why?
|
| Nanostructures | 1 | 2015 | 23 | 0.110 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cell Line | 1 | 2015 | 84 | 0.110 |
Why?
|
| Genetic Engineering | 1 | 2014 | 5 | 0.110 |
Why?
|
| Mutagenesis | 1 | 2014 | 7 | 0.110 |
Why?
|
| Antibody Formation | 1 | 2014 | 1 | 0.110 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 9 | 0.100 |
Why?
|
| Nanotechnology | 1 | 2013 | 29 | 0.100 |
Why?
|
| Serine Proteases | 1 | 2012 | 2 | 0.100 |
Why?
|
| Cloning, Molecular | 1 | 2012 | 9 | 0.100 |
Why?
|
| Disulfides | 1 | 2012 | 6 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 22 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2012 | 7 | 0.100 |
Why?
|
| Biological Transport | 1 | 2012 | 18 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 23 | 0.090 |
Why?
|
| Surface Properties | 1 | 2012 | 77 | 0.090 |
Why?
|
| Kinetics | 1 | 2012 | 80 | 0.090 |
Why?
|
| Gene Knockout Techniques | 2 | 2021 | 10 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 47 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2021 | 19 | 0.080 |
Why?
|
| Burkitt Lymphoma | 2 | 2021 | 2 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 9 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 12 | 0.070 |
Why?
|
| Aged | 2 | 2024 | 703 | 0.070 |
Why?
|
| Mutation | 2 | 2019 | 132 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 15 | 0.060 |
Why?
|
| Cell Movement | 2 | 2019 | 61 | 0.060 |
Why?
|
| Middle Aged | 2 | 2024 | 967 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 1 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2024 | 5 | 0.060 |
Why?
|
| Adult | 2 | 2024 | 1567 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2024 | 115 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2024 | 115 | 0.050 |
Why?
|
| Epitopes | 1 | 2022 | 3 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2022 | 4 | 0.050 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 1 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 1 | 2021 | 1 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 11 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 6 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 1 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 4 | 0.040 |
Why?
|
| Aerobiosis | 1 | 2021 | 3 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 17 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 16 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 14 | 0.040 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2021 | 7 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2021 | 13 | 0.040 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2021 | 8 | 0.040 |
Why?
|
| Ligands | 1 | 2020 | 55 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 1 | 0.040 |
Why?
|
| Transgenes | 1 | 2020 | 6 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 44 | 0.040 |
Why?
|
| Protein Binding | 1 | 2020 | 115 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 9 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 177 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 14 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 40 | 0.040 |
Why?
|
| Computer Graphics | 1 | 2019 | 9 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2019 | 22 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2019 | 31 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 3 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 8 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2017 | 3 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 1 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2017 | 3 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 9 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 15 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 5 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2017 | 13 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 36 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 60 | 0.030 |
Why?
|
| Melanoma | 1 | 2017 | 28 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 37 | 0.030 |
Why?
|
| Crystallization | 1 | 2017 | 83 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 140 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 66 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 17 | 0.030 |
Why?
|
| Factor VIII | 1 | 2016 | 1 | 0.030 |
Why?
|
| Antibodies, Catalytic | 1 | 2016 | 1 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2016 | 1 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2016 | 2 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 19 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 34 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 124 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 25 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 83 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 9 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 262 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2014 | 1 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 2014 | 1 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hybridomas | 1 | 2014 | 2 | 0.030 |
Why?
|
| CHO Cells | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cricetulus | 1 | 2014 | 18 | 0.030 |
Why?
|
| Young Adult | 1 | 2016 | 787 | 0.020 |
Why?
|
| HIV Infections | 1 | 2014 | 104 | 0.020 |
Why?
|